Explore the words cloud of the PreventSepticShock project. It provides you a very rough idea of what is the project "PreventSepticShock" about.
The following table provides information about the project.
Coordinator |
SPHINGOTEC GMBH
Organization address contact info |
Coordinator Country | Germany [DE] |
Project website | http://www.sphingotec.com/brochures-list/sphingotest-bio-adm/ |
Total cost | 2˙137˙500 € |
EC max contribution | 2˙137˙500 € (100%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SMEINST-2-2014 |
Funding Scheme | SME-2 |
Starting year | 2015 |
Duration (year-month-day) | from 2015-04-01 to 2017-03-31 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | SPHINGOTEC GMBH | DE (HOHEN NEUENDORF) | coordinator | 2˙137˙500.00 |
Sepsis is a life-threatening condition that arises when the body's response to an infection damages its own tissues and organs. Although sepsis is initiated by infection, it is not the infection per se, which kills the patient, but rather the body’s response to it, in particular, the development of a shock, which is initiated by deterioration of the blood vessel system, hypotension, insufficient oxygenation of organs and finally their functional breakdown. For a clinician this situation occurs suddenly and there is no diagnostic tool to predict this event early enough to initiate adequate measures to guide the patient and prevent its death. Despite of large efforts and developments in the last decade septic shock is still the world biggest killer causing 5-6 million deaths a year worldwide. Thus the prediction of septic shock and stratification of high risk patients is still an unmet medical need. The novel bioreactive Adrenomedullin (bio-ADM) assay of Sphingotec is the first unprecedented analytical assay which stratified in a pilot study sepsis patients who have the risk to die from a septic shock with very high confidentiality. Thus adequate measures to restore blood pressure can be introduced in time and life can be saved. Feasibility studies elucidating all clinical and commercialisation aspects have given excellent prospects for bio-ADM. Thus, in the project the bio-ADM assay will be used in an observation study with 1000 ICU patients suffering from sepsis to validate the power of the novel biomarker and to indicate a cut-off for bio-ADM. Furthermore, the project is dedicated to conduct technical work to bring the marker to automation and point of care platforms of diagnostic partners to guarantee broad application after the project, and to carry out measures to disseminate and explore the project results to ensure quick penetration of an up to 500 million € diagnostic market. In this way the project will initiate dynamic and robust growth of the applicant.
Ethical documents | Documents, reports | 2019-07-25 12:58:35 |
CE labelling | Other | 2019-07-25 12:58:35 |
PreventSepticShock marketing website | Websites, patent fillings, videos etc. | 2019-07-25 12:58:34 |
Presentation of PreventSepticShock | Documents, reports | 2019-07-25 12:58:35 |
Scientific dissemination material | Documents, reports | 2019-07-25 12:58:35 |
Take a look to the deliverables list in detail: detailed list of PreventSepticShock deliverables.
year | authors and title | journal | last update |
---|---|---|---|
2016 |
Rudovich N1, Pivovarova O, Bernigau W, Sparwasser A, Tacke C, Murahovshi V, Mertes G, Birkenfeld AL, Bergmann A, Weickert MO, Pfeiffer AF. Modulation of circulating vasoactive peptides and extracellular matrix proteins are two novel mechanisms in the cardioprotective action of acarbose. published pages: , ISSN: , DOI: |
Minerva Endocrinol. 2016 Dec;41(4):456-68. Epub 2016 Mar 23. | 2019-07-25 |
2017 |
Mattia Arrigo, Quynh A. Truong, Jackie Szymonifka, Mercedes Rivas-Lasarte, Heli Tolppanen, Malha Sadoune, Etienne Gayat, Alain Cohen-Solal, Frank Ruschitzka, James L. Januzzi, Jagmeet P. Singh, Alexandre Mebazaa Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy published pages: , ISSN: 1099-5129, DOI: 10.1093/europace/euw305 |
EP Europace | 2019-07-25 |
2017 |
Heli Tolppanen, Mercedes Rivas-Lasarte, Johan Lassus, Jordi Sans-Roselló, Oliver Hartmann, Matias Lindholm, Mattia Arrigo, Tuukka Tarvasmäki, Lars Köber, Holger Thiele, Kari Pulkki, Jindrich Spinar, John Parissis, Marek Banaszewski, Jose Silva-Cardoso, Valentina Carubelli, Alessandro Sionis, Veli-Pekka Harjola, Alexandre Mebazaa Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock published pages: , ISSN: 2110-5820, DOI: 10.1186/s13613-016-0229-2 |
Annals of Intensive Care 7/1 | 2019-07-25 |
2017 |
Tim-Philipp Simon, Lukas Martin, Sabine Doemming, Andreas Humbs, Christian Bruells, Ruedger Kopp, Oliver Hartmann, Joachim Struck, Andreas Bergmann, Gernot Marx, Tobias Schuerholz Plasma adrenomedullin in critically ill patients with sepsis after major surgery: A pilot study published pages: 68-72, ISSN: 0883-9441, DOI: 10.1016/j.jcrc.2016.10.017 |
Journal of Critical Care 38 | 2019-07-25 |
2015 |
Matthew F. Yuyun, Hafid K. Narayan, Leong L. Ng Prognostic Significance of Adrenomedullin in Patients With Heart Failure and With Myocardial Infarction published pages: 986-991, ISSN: 0002-9149, DOI: 10.1016/j.amjcard.2015.01.027 |
The American Journal of Cardiology 115/7 | 2019-07-25 |
2015 |
Abraham Schoe, Emile F. Schippers, Joachim Struck, Stefan Ebmeyer, Robert J.M. Klautz, Evert de Jonge, Jaap T. van Dissel Postoperative Pro-Adrenomedullin Levels Predict Mortality in Thoracic Surgery Patients published pages: 373-381, ISSN: 0090-3493, DOI: 10.1097/CCM.0000000000000709 |
Critical Care Medicine 43/2 | 2019-07-25 |
2017 |
Pietro Caironi, Roberto Latini, Joachim Struck, Oliver Hartmann, Andreas Bergmann, Giuseppe Maggio, Marco Cavana, Gianni Tognoni, Antonio Pesenti, Luciano Gattinoni, Serge Masson Circulating biologically active adrenomedullin (bio-ADM) predicts hemodynamic support requirement and mortality during sepsis published pages: , ISSN: 0012-3692, DOI: 10.1016/j.chest.2017.03.035 |
Chest | 2019-07-25 |
2016 |
Wesley H. Self, Alan B. Storrow, Oliver Hartmann, Tyler W. Barrett, Gregory J. Fermann, Alan S. Maisel, Joachim Struck, Andreas Bergmann, Sean P. Collins Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure published pages: 257-262, ISSN: 0735-6757, DOI: 10.1016/j.ajem.2015.10.033 |
The American Journal of Emergency Medicine 34/2 | 2019-07-25 |
2017 |
Matthew F. Yuyun, Hafid K. Narayan, Paulene A. Quinn, Joachim Struck, Andreas Bergmann, Oliver Hartmann, Leong L. Ng Prognostic value of human mature adrenomedullin in patients with acute myocardial infarction published pages: 42-50, ISSN: 1558-2027, DOI: 10.2459/JCM.0000000000000299 |
Journal of Cardiovascular Medicine 18/1 | 2019-07-25 |
2016 |
Chris Berrie Adrenomedullin Plasma Levels Predictive of Mortality in Intensive Care Unit: Presented at ISICEM published pages: , ISSN: , DOI: |
2019-07-25 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREVENTSEPTICSHOCK" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PREVENTSEPTICSHOCK" are provided by the European Opendata Portal: CORDIS opendata.
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More